Bio-path holdings inc (BPTH)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flow from operating activities
Net loss

-10,411

-8,599

-8,119

-8,958

-8,179

-8,583

-8,841

-8,234

-8,542

-7,023

-6,227

-5,323

-5,280

-6,750

-6,838

-6,776

-5,959

-5,467

-5,604

-5,245

-5,389

-4,519

-3,711

-3,956

-3,114

-3,266

-2,908

-2,355

-2,716

-2,582

-2,954

-2,617

-2,292

-2,363

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Technology impairment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

345

345

0

0

0

-

-

-

-

Common stock issed for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

18

18

0

0

0

-

-

-

-

Stock-based compensation

697

684

660

629

587

554

534

549

668

793

909

973

938

784

636

503

372

369

359

378

409

404

395

883

774

704

653

58

60

63

64

176

282

382

0

0

0

Amortization of technology license

-

-

-

-

-

161

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of right of use assets

87

96

75

56

28

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization

-

-

-

-

-

-

-

-

-

160

160

161

161

161

161

161

161

161

161

160

160

161

160

160

160

160

160

168

177

185

199

203

208

211

0

0

0

Depreciation

86

134

183

232

265

265

264

275

284

251

197

130

66

43

41

41

41

41

41

31

20

10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-2,374

-2,667

-4,087

-3,309

-1,713

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Increase) decrease in operating assets
Prepaid drug product for testing

337

444

508

-678

-829

-785

-396

740

879

741

457

13

-234

-184

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

244

0

0

0

Prepaid drug product for testing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-51

-137

153

-143

68

-16

-189

42

-49

166

155

-64

0

0

0

Other current assets

-835

-15

458

241

1,043

450

-230

-407

-532

-549

-401

-265

112

723

712

1,023

628

79

5

81

-35

36

144

125

103

21

4

-0

13

-5

42

50

38

24

0

0

0

Increase (decrease) in operating liabilities
Accounts payable and accrued expenses

227

-168

183

-6

344

536

190

459

334

-12

-111

-279

-317

-146

385

121

284

375

197

358

195

267

109

65

129

-34

-94

24

43

13

63

22

58

69

0

0

0

Lease liabilities

72

79

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,856

-5,981

-5,005

-5,159

-4,952

-4,677

-3,817

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-8,888

-8,361

-7,399

-6,977

-6,468

-6,124

-7,066

-7,124

-7,781

-7,957

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-1,991

-1,803

-1,425

-1,149

0

0

0

Cash flow from investing activities
Purchase of exclusive license - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

25

132

157

162

170

0

0

0

Purchases of furniture, fixtures & equipment

-

-

-

-

-

17

17

17

131

538

851

876

762

338

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-17

-17

-17

-131

-538

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-132

-157

-162

-170

0

0

0

Cash flow from financing activities
Proceeds from convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Cash repayment of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Net proceeds from sale of common stock

7,289

26,700

19,412

20,591

20,591

1,180

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

13,740

16,627

18,837

5,330

6,030

3,851

1,856

1,600

1,473

902

1,398

2,033

0

0

0

Net proceeds from exercise of warrants

214

1,083

1,083

914

869

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,247

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

7,503

27,783

20,495

21,505

21,460

1,180

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

1,473

902

1,398

2,033

0

0

0

Net increase (decrease) in cash

-1,385

19,422

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash activities
Non-cash investing activities
Net increase (decrease) in cash

-

-

-

-

-

-

-

-

-2,827

-3,410

-6,676

1,958

638

521

1,444

-6,856

-5,981

-5,005

-4,781

-4,641

-4,365

10,307

10,535

13,793

16,531

3,017

3,767

1,764

-288

-418

-650

-1,059

-188

713

0

0

0

Interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

Capital expenditures included in accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued upon conversion of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-